SA521421448B1 - مترافقات جديدة من مونتيلوكاست وببتيدات - Google Patents
مترافقات جديدة من مونتيلوكاست وببتيداتInfo
- Publication number
- SA521421448B1 SA521421448B1 SA521421448A SA521421448A SA521421448B1 SA 521421448 B1 SA521421448 B1 SA 521421448B1 SA 521421448 A SA521421448 A SA 521421448A SA 521421448 A SA521421448 A SA 521421448A SA 521421448 B1 SA521421448 B1 SA 521421448B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- peptide
- montelukast
- containing compound
- compounds
- formula
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title abstract 2
- 229960005127 montelukast Drugs 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- LLGQICNFACCGPR-LDXVMNHOSA-N 2-[1-[[(1r)-1-[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-(2-prop-1-en-2-ylphenyl)propyl]sulfanylmethyl]cyclopropyl]acetic acid Chemical compound CC(=C)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 LLGQICNFACCGPR-LDXVMNHOSA-N 0.000 abstract 2
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000014617 hemorrhoid Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018105703 | 2018-09-14 | ||
| CN2018119072 | 2018-12-04 | ||
| PCT/CN2019/105832 WO2020052677A1 (en) | 2018-09-14 | 2019-09-14 | New conjugates of montelukast and peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA521421448B1 true SA521421448B1 (ar) | 2024-03-14 |
Family
ID=69777394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA521421448A SA521421448B1 (ar) | 2018-09-14 | 2021-03-11 | مترافقات جديدة من مونتيلوكاست وببتيدات |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11680082B2 (https=) |
| EP (2) | EP4253404A3 (https=) |
| JP (1) | JP7759693B2 (https=) |
| KR (1) | KR102946621B1 (https=) |
| CN (2) | CN111601618A (https=) |
| AU (1) | AU2019338582B2 (https=) |
| BR (1) | BR112021004823A2 (https=) |
| CA (1) | CA3112420A1 (https=) |
| DK (1) | DK3678705T5 (https=) |
| ES (1) | ES2956509T3 (https=) |
| FI (1) | FI3678705T3 (https=) |
| HR (1) | HRP20230946T1 (https=) |
| HU (1) | HUE062848T2 (https=) |
| IL (1) | IL281426A (https=) |
| LT (1) | LT3678705T (https=) |
| MX (1) | MX2021002657A (https=) |
| MY (1) | MY205435A (https=) |
| PL (1) | PL3678705T3 (https=) |
| PT (1) | PT3678705T (https=) |
| RS (1) | RS64436B1 (https=) |
| SA (1) | SA521421448B1 (https=) |
| SG (1) | SG11202102119RA (https=) |
| SI (1) | SI3678705T1 (https=) |
| SM (1) | SMT202300210T1 (https=) |
| TW (1) | TWI875712B (https=) |
| WO (1) | WO2020052677A1 (https=) |
| ZA (1) | ZA202101398B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020000029A (es) * | 2017-07-05 | 2020-08-06 | Jiangyin Mucocare Pharmaceutical Co Ltd | Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon. |
| MX2022003057A (es) * | 2019-09-14 | 2022-06-16 | Jiangyin Usun Pharmaceutical Co Ltd | Nuevos peptidos. |
| CA3160167A1 (en) * | 2019-12-02 | 2021-06-10 | Ming Gu | Peptides and their use in the treatment of inflammation |
| WO2021207606A1 (en) * | 2020-04-10 | 2021-10-14 | University Of Georgia Research Foundation, Inc. | Methods for treatment of coronavirus infections |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| KR102596264B1 (ko) * | 2020-11-30 | 2023-11-01 | 주식회사 바이오빛 | 기능성 펩티드가 결합된 생체적합 폴리펩티드를 포함하는 염증 질환의 억제용 조성물 |
| US20240165247A1 (en) * | 2021-03-17 | 2024-05-23 | Jiangyin Usun Pharmaceutical Co., Ltd. | New peptide conjugates |
| WO2022193186A1 (en) * | 2021-03-17 | 2022-09-22 | Jiangyin Usun Pharmaceutical Co., Ltd. | New diagnostic and therapeutic agents |
| WO2023225107A1 (en) * | 2022-05-17 | 2023-11-23 | Emory University | Diroximel fumarate, inhalation administration methods, pharmaceutical uses and compositions |
| EP4665372A1 (en) * | 2023-02-13 | 2025-12-24 | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | New multi-functional oligopeptides |
| WO2024260465A1 (en) * | 2023-06-22 | 2024-12-26 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | New multi-functional oligopeptides |
| TW202535906A (zh) * | 2023-10-23 | 2025-09-16 | 大陸商安利提沙（上海）製藥有限公司 | 新型短鏈肽及其衍生物 |
| KR20250075990A (ko) * | 2023-11-22 | 2025-05-29 | 한도숙 | 상처 치료 또는 피부 주름형성 억제용 조성물 |
| WO2025195444A1 (en) | 2024-03-20 | 2025-09-25 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | New use of peptides derived from vasoactive intestinal peptide |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| WO2003020200A2 (en) * | 2000-11-16 | 2003-03-13 | New River Pharmaceuticals Inc. | A novel pharmaceutical compound and methods of making and using same |
| EP2316468A1 (en) * | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| PL374646A1 (en) | 2002-07-08 | 2005-10-31 | Pliva-Istrazivacki Institutt D.O.O. | Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
| US20050107612A1 (en) | 2002-12-30 | 2005-05-19 | Dr. Reddy's Laboratories Limited | Process for preparation of montelukast and its salts |
| CA2522007A1 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Methods of preventing or treating respiratory conditions |
| JP4764818B2 (ja) * | 2003-04-11 | 2011-09-07 | メディミューン，エルエルシー | 組換えｉｌ−９抗体およびその使用 |
| CN101123878A (zh) | 2003-07-29 | 2008-02-13 | 信号研发控股有限责任公司 | 氨基酸前药 |
| US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| ES2337915T3 (es) | 2004-10-27 | 2010-04-30 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Conjugados con adtividad antiinflamatoria. |
| TW200740441A (en) * | 2005-06-17 | 2007-11-01 | Combinatorx Inc | Methods and reagents for the treatment of inflammatory disorders |
| CA2773737C (en) * | 2009-09-09 | 2021-11-16 | Pharmain Corporation | Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same |
| CN102068432A (zh) | 2011-01-11 | 2011-05-25 | 李仲昆 | 一种由他定类和白三烯拮抗剂组成的外用复方组合物 |
| WO2012112690A2 (en) * | 2011-02-16 | 2012-08-23 | Fabius Biotechnology | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains |
| CN116898848A (zh) | 2012-01-18 | 2023-10-20 | 苏州泰飞尔医药有限公司 | 治疗肺部疾病的高穿透力前药组合物和医药组合物 |
| WO2014164285A2 (en) * | 2013-03-13 | 2014-10-09 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of vasculitis |
| US20160060328A1 (en) * | 2013-10-25 | 2016-03-03 | Lpath, Inc. | Compositions and methods for binding cysteinyl leukotrienes (cyslts) for treatment of disease |
| WO2016044095A1 (en) * | 2014-09-15 | 2016-03-24 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
| KR102468519B1 (ko) * | 2015-07-20 | 2022-11-21 | 장인 벵트 아이. 사무엘손 인스티튜트 오브 라이프 사이언스 컴퍼니 리미티드 | 피부 염증의 억제에서의 홍합 접착 단백질 제품 및 이의 적용 |
| BR112019024563A2 (pt) | 2017-05-24 | 2020-06-23 | Transfert Plus S.E.C. | Compostos peptídicos, compostos conjugados e usos dos mesmos para tratar doenças inflamatórias |
| JP7198785B2 (ja) * | 2017-07-05 | 2023-01-04 | ジャンイン ユスン ファーマシューティカル カンパニー，リミテッド | ペプチドの抗炎症的使用 |
| MX2020000029A (es) * | 2017-07-05 | 2020-08-06 | Jiangyin Mucocare Pharmaceutical Co Ltd | Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon. |
-
2019
- 2019-09-14 CN CN201980004399.1A patent/CN111601618A/zh active Pending
- 2019-09-14 ES ES19856467T patent/ES2956509T3/es active Active
- 2019-09-14 SG SG11202102119RA patent/SG11202102119RA/en unknown
- 2019-09-14 CA CA3112420A patent/CA3112420A1/en active Pending
- 2019-09-14 FI FIEP19856467.6T patent/FI3678705T3/fi active
- 2019-09-14 SI SI201930561T patent/SI3678705T1/sl unknown
- 2019-09-14 EP EP23176152.9A patent/EP4253404A3/en active Pending
- 2019-09-14 SM SM20230210T patent/SMT202300210T1/it unknown
- 2019-09-14 HU HUE19856467A patent/HUE062848T2/hu unknown
- 2019-09-14 PT PT198564676T patent/PT3678705T/pt unknown
- 2019-09-14 BR BR112021004823-5A patent/BR112021004823A2/pt unknown
- 2019-09-14 KR KR1020217010829A patent/KR102946621B1/ko active Active
- 2019-09-14 CN CN202310240501.6A patent/CN116785447B/zh active Active
- 2019-09-14 MY MYPI2021001220A patent/MY205435A/en unknown
- 2019-09-14 LT LTEPPCT/CN2019/105832T patent/LT3678705T/lt unknown
- 2019-09-14 RS RS20230654A patent/RS64436B1/sr unknown
- 2019-09-14 AU AU2019338582A patent/AU2019338582B2/en active Active
- 2019-09-14 WO PCT/CN2019/105832 patent/WO2020052677A1/en not_active Ceased
- 2019-09-14 DK DK19856467.6T patent/DK3678705T5/da active
- 2019-09-14 JP JP2021514112A patent/JP7759693B2/ja active Active
- 2019-09-14 MX MX2021002657A patent/MX2021002657A/es unknown
- 2019-09-14 HR HRP20230946TT patent/HRP20230946T1/hr unknown
- 2019-09-14 PL PL19856467.6T patent/PL3678705T3/pl unknown
- 2019-09-14 EP EP19856467.6A patent/EP3678705B1/en active Active
- 2019-09-14 US US16/645,355 patent/US11680082B2/en active Active
- 2019-09-16 TW TW108133243A patent/TWI875712B/zh active
-
2021
- 2021-03-01 ZA ZA2021/01398A patent/ZA202101398B/en unknown
- 2021-03-11 SA SA521421448A patent/SA521421448B1/ar unknown
- 2021-03-11 IL IL281426A patent/IL281426A/en unknown
-
2023
- 2023-05-12 US US18/316,496 patent/US20230348536A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521421448B1 (ar) | مترافقات جديدة من مونتيلوكاست وببتيدات | |
| MX2022007846A (es) | Derivados carboxi con propiedades antiinflamatorias. | |
| EA201170193A1 (ru) | Новые содержащие серу липиды для применения в качестве пищевой добавки или в качестве лекарственного средства | |
| EA202190196A1 (ru) | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| PE20181376A1 (es) | Analogos del egf(a) con sustituyentes de acidos grasos | |
| MX2020007994A (es) | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). | |
| DOP2022000291A (es) | Nuevo inhibidor de la secreción de ácido y uso del mismo | |
| MX2022003057A (es) | Nuevos peptidos. | |
| MX2020008116A (es) | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat). | |
| MX2025011636A (es) | Metodo mejorado para producir aplicaciones relacionadas con la colagenasa | |
| WO2012059442A3 (en) | Neurotrypsin inhibitors | |
| SA522441650B1 (ar) | مثبطات فوسفوينوسيتيد 3-كيناز الموضعية | |
| MX2024006556A (es) | Inhibidores de peptido del receptor de interleucina-23. | |
| ME01595B (me) | Benzamidinska jedinjenja koja su korisna kao inhibitori histonske deacetilaze | |
| DOP2025000079A (es) | Compuesto de anillo fusionado y agente farmacéutico que contiene el mismo | |
| EA200601462A1 (ru) | Соединения для лечения заболеваний | |
| EA201001138A1 (ru) | Антибактериальные композиции | |
| MX388014B (es) | Composición limpiadora líquida sin jabón que comprende ácido caprílico. | |
| BR112020006576A8 (pt) | Sal ácido conjugado de n, n-dimetilglicina com ácido orgânico, composição e utilização. | |
| MX2019004312A (es) | Odorante de lirio del valle. | |
| CA3217100A1 (en) | Novel anti-fibrotic drugs | |
| EA202191158A1 (ru) | Новый способ получения n,n'-бис[2-(1н-имидазол-4-ил)этил]малонамида | |
| GEAP202416568A (en) | Triazolone derivative salt as neutrophil elastase inhibitor | |
| MA49478B1 (fr) | Nouveaux conjugués de montélukast et de peptides |